Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1941 1
1950 1
1963 1
1964 1
1967 1
1972 2
1974 1
1975 8
1976 1
1977 5
1978 6
1979 16
1980 17
1981 32
1982 34
1983 37
1984 43
1985 62
1986 65
1987 77
1988 77
1989 66
1990 99
1991 91
1992 124
1993 140
1994 192
1995 191
1996 242
1997 254
1998 299
1999 324
2000 371
2001 424
2002 539
2003 574
2004 839
2005 994
2006 1151
2007 1301
2008 1513
2009 1769
2010 2081
2011 2385
2012 2895
2013 3359
2014 3951
2015 4568
2016 5101
2017 5425
2018 6191
2019 7092
2020 8558
2021 9613
2022 11266
2023 10918
2024 4232

Text availability

Article attribute

Article type

Publication date

Search Results

88,973 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Zhao
Page 1
Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week.
Harrington J, Piccini JP, Alexander JH, Granger CB, Patel MR. Harrington J, et al. J Am Coll Cardiol. 2023 Feb 28;81(8):771-779. doi: 10.1016/j.jacc.2022.11.057. J Am Coll Cardiol. 2023. PMID: 36813377 Free article. Review.
Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in anticoagulation because it is involved primarily in thrombus formation and plays a much smaller role in clotting and hemostasis. This suggests that the inhibition of FXI/XIa could preve …
Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in anticoagulation because it is involved primarily in …
First-in-human study of milvexian, an oral, direct, small molecule factor XIa inhibitor.
Perera V, Wang Z, Luettgen J, Li D, DeSouza M, Cerra M, Seiffert D. Perera V, et al. Clin Transl Sci. 2022 Feb;15(2):330-342. doi: 10.1111/cts.13148. Epub 2021 Sep 24. Clin Transl Sci. 2022. PMID: 34558200 Free PMC article. Clinical Trial.
Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and treat thrombotic events. ...
Milvexian (BMS-986177/JNJ-70033093) is a small molecule, active-site inhibitor of factor XIa (FXIa) being developed to prevent and tr …
Factor XI/XIa Inhibitors Here We Go Again!
Spears J, Strony J, Kowey PR. Spears J, et al. Am J Med. 2023 Jun;136(6):512-513. doi: 10.1016/j.amjmed.2023.01.016. Epub 2023 Feb 2. Am J Med. 2023. PMID: 36739063 No abstract available.
Factor XIa Inhibitors in Anticoagulation Therapy: Recent Advances and Perspectives.
Xie Z, Meng Z, Yang X, Duan Y, Wang Q, Liao C. Xie Z, et al. J Med Chem. 2023 Apr 27;66(8):5332-5363. doi: 10.1021/acs.jmedchem.2c02130. Epub 2023 Apr 10. J Med Chem. 2023. PMID: 37037122 Review.
Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be an effective and safe target for anticoagulant discovery with limited or no bleeding. ...
Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be an effective and safe target for anticoag …
Completely Delusional.
Xia J. Xia J. Schizophr Bull. 2023 Feb 8:sbad004. doi: 10.1093/schbul/sbad004. Online ahead of print. Schizophr Bull. 2023. PMID: 36752877 No abstract available.
Factor XIa Inhibitors as New Anticoagulants.
Quan ML, Pinto DJP, Smallheer JM, Ewing WR, Rossi KA, Luettgen JM, Seiffert DA, Wexler RR. Quan ML, et al. J Med Chem. 2018 Sep 13;61(17):7425-7447. doi: 10.1021/acs.jmedchem.8b00173. Epub 2018 May 18. J Med Chem. 2018. PMID: 29775297 Review.
Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhib …
Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded effica …
Who's Unreachable?
Xia J. Xia J. Schizophr Bull. 2023 Apr 12:sbad055. doi: 10.1093/schbul/sbad055. Online ahead of print. Schizophr Bull. 2023. PMID: 37043611 No abstract available.
Efficacy and Safety of Oral Factor XIa Inhibitors in Stroke Prevention: A Systematic Review and Meta-Analysis.
Palaiodimou L, Papagiannopoulou G, Katsanos AH, Eleftheriou A, Karapanayiotides T, Mitsias PD, Lemmens R, Molina CA, Alexandrov A, Caso V, Shoamanesh A, Sharma M, Tsivgoulis G. Palaiodimou L, et al. J Clin Med. 2023 Aug 26;12(17):5562. doi: 10.3390/jcm12175562. J Clin Med. 2023. PMID: 37685629 Free PMC article. Review.
RESULTS: Four phase II dose-finding RCTs were included, comprising a total of 4732 patients treated with factor XIa inhibitors versus 1798 controls. Treatment with factor XIa inhibitors did not reduce the risk of IS compared to controls (RR: 0.89; 95% CI: 0.67-1.17) …
RESULTS: Four phase II dose-finding RCTs were included, comprising a total of 4732 patients treated with factor XIa inhibitors versus …
Targeting factor XI and factor XIa to prevent thrombosis.
Gailani D, Gruber A. Gailani D, et al. Blood. 2024 Apr 11;143(15):1465-1475. doi: 10.1182/blood.2023020722. Blood. 2024. PMID: 38142404 Review.
There is considerable interest in the plasma zymogen factor XI (FXI) and its protease form factor XIa (FXIa) as drug targets for treating and preventing thrombosis. ...
There is considerable interest in the plasma zymogen factor XI (FXI) and its protease form factor XIa (FXIa) as drug targets for trea …
88,973 results
You have reached the last available page of results. Please see the User Guide for more information.